Olaratumab + Doxorubicin + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Soft Tissue Sarcoma
Conditions
Soft Tissue Sarcoma
Trial Timeline
Sep 14, 2015 → Jun 27, 2024
NCT ID
NCT02451943About Olaratumab + Doxorubicin + Placebo
Olaratumab + Doxorubicin + Placebo is a phase 3 stage product being developed by Eli Lilly for Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02451943. Target conditions include Soft Tissue Sarcoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02451943 | Phase 3 | Completed |
Competing Products
20 competing products in Soft Tissue Sarcoma